Kicking off the second day of the European Society of Cardiology (ESC) Congress, researchers presented data suggesting that a single-pill combination of anti-hypertensive drugs could be a viable option as a first-line treatment.
As per results presented at the ESC Congress on 30 August, a Phase III placebo-controlled trial (NCT04518306) investigated a single-pill combination therapy for the initial treatment of hypertension. Dubbed GMRx2, the pill combines the active ingredients telmisartan, an angiotensin II antagonist, amlodipine, and indapamide.
Go deeper with GlobalData
Amlodipine is a voltage-dependent L Type calcium channel blocker and indapamide is a diuretic drug. Boehringer Ingelheim markets the former drug as Micardis, whilst Viatris sells amplodipine as Norvasc, and Mylan markets the indapamide as Tensaid. London, UK-based George Medicines is developing this triple combination and filed a US Food and Drug Administration new drug application for the pill in August 2024.
“Globally, most people treated for high blood pressure (BP) do not achieve adequate control, primarily due to continued use of low-efficacy regimens including monotherapy,” said Dr. Anthony Rogers, the acting director of the cardiovascular division of the George Institute for Global Health, Sydney, Australia. “Single-pill combinations of different low-dose drugs hold promise for improving hypertension management by virtue of additive benefits, rapid action and a low risk of adverse events,” he said while presenting the data. George Medicines is a spinout from George Institute for Global Health.
Rogers, the principal investigator of the international study, shared trial results showing that, in a population with mild-to-moderate blood pressure elevation, both dose-versions of the single pill combination were well-tolerated and achieved clinically relevant blood pressure reductions compared with placebo. Furthermore, clinic blood pressure control was achieved in 37% of participants with placebo, compared to 65% and 70% of patients in the GMRx2 quarter- and half-dose cohorts, respectively.
“The availability of a single-pill combination could help to reduce current therapeutic inertia, helping patients achieve BP control quickly in a small number of steps, with potential benefits for improved adherence,” explained Rodgers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
